Rankings/Qure.ai
Qure.ai logo

Qure.ai

NativeAI NativePrivateUpdated November 15, 2026

AI medical imaging company whose deep learning models interpret chest X-rays and CT scans at scale, deployed across 100+ countries for...

Website
qure.ai
Founded
2016
CEO
Prashant Warier
HQ
Mumbai, India
Stage
Private
Revenue
Not disclosed
Total Funding
$157M
Employees
201-500
Flag a data issue
Healthcare ToolsHealthcare
50.8Bluescore
Momentum62.0
Market MapCategory Leaders
Rank change (7d)▲ 2

Executive Summary

Updated Nov 15, 2026

What they do

  • Deep learning models that read chest X-rays, head CTs and chest CTs
  • Lung nodule detection and follow-up management suite for early lung cancer detection
  • Triage and notification software for stroke, brain bleeds and trauma on head CT

Why it matters

  • Says it has 26 FDA-cleared indications and deployments in 4,000+ hospitals worldwide
  • Microsoft Precision Imaging Network integration makes its lung cancer suite easier to deploy in the US
  • Large public-health programs in TB, lung cancer and pandemic readiness show it works at population scale

Best fit

  • Health systems running lung cancer screening or incidental nodule follow-up programs
  • Emergency departments and teleradiology groups that need fast chest X-ray and head CT triage
  • Ministries of health, NGOs and pharma running TB or lung screening at scale

Watch-outs

  • Net losses reportedly widened to about ₹90 crore in FY25 despite revenue growth
  • US commercial presence is still being built, and its North America sales leadership is new
  • Clearances are spread across many narrow indications, so check the scope of each one

Products & Offerings

qXR

Chest X-ray AI that detects and localizes many findings, including nodules, TB, pneumothorax and tube placement, through its FDA-cleared qXR-Detect and related modules.

PlatformEnterpriseFlagship

qER

FDA-cleared head CT triage software that flags intracranial bleeds, mass effect, midline shift and fractures for urgent review.

EnterpriseEnterpriseCore Platform

Lung Cancer Detection and Management Suite (qXR-LN, qCT)

Software that detects nodules on X-ray and CT and tracks patients through follow-up care, and is available through Microsoft's Precision Imaging Network.

PlatformEnterpriseHigh Growth

Aira

AI clinical decision support system that has received Class IIb CE certification in Europe.

EnterpriseEnterpriseEmerging

QureOS

AI-powered digital health operating system that helps health systems in low- and middle-income countries run screening and care pathways.

PlatformEnterpriseLive2024

Latest News

Analyst VerdictShortlist

Updated Nov 15, 2026

Qure.ai is one of the most widely deployed imaging AI vendors and has an unusually broad set of FDA clearances for chest X-ray. Health systems buying AI for chest X-ray, lung nodules or head CT triage should put it on the shortlist next to rivals such as Aidoc, Lunit and Annalise.ai. In due diligence, check its US support capacity, how it integrates with your PACS, and whether it has the funding to stay viable as losses grow.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 10, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 15, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 9, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Nov 15, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026Research agents (estimate)
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
Nov 15, 2026Research agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Qure.ai's Bluescore of 50.8 rests most on Data & Model Moat (6.8, top 11%) and Business Model & Revenue (4.9, 66th percentile). Its weakest area is Investment Momentum (3.8, 34th percentile).

In plain English

Qure.ai ranks #95 of 247 with a Bluescore of 50.8 out of 100, lifted mainly by Data & Model Moat, where its score of 6.8 of 10 adds 12.9 of 19 points and sits at the 89th percentile among the AI250. Talent & Research (3.7 of 10, 47th percentile) and Investment Momentum (3.8 of 10, 34th percentile) hold it back, with Investment Momentum adding just 3.8 of 10 points. The biggest opportunity is Business Model & Revenue, a 21% weight where a score of 4.9 of 10 leaves 10.8 points on the table, the most of any dimension.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
4.9
+10.2 of 21 pts · 66th pct
D2 · Product Depth (21%)
5.3
+11.2 of 21 pts · 65th pct
D3 · Data & Model Moat (19%)
6.8
+12.9 of 19 pts · Top 11%
D4 · Talent & Research (16%)
3.7
+5.9 of 16 pts · 47th pct
D5 · Customer Adoption (13%)
5.2
+6.8 of 13 pts · 50th pct
D6 · Investment Momentum (10%)
3.8
+3.8 of 10 pts · 34th pct

Risks

Updated Nov 15, 2026

Losses are widening and funding is concentrated in a 2024 Series D
Medium
Faces crowded competition from Aidoc, Lunit, Annalise.ai and the imaging platforms of major OEMs
Medium
Much of its revenue comes from emerging markets, where public-sector budgets and grants can be unpredictable
Medium
US reimbursement for imaging AI remains limited, which makes return on investment hard to prove
Medium
A planned IPO could change its pricing, priorities or how it engages with customers
Low
Feedback